- Home
- LXEO vs ACP Comparison
LXEO vs ACP Comparison
Compare LXEO & ACP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LXEO | ACP |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.5M | 675.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | LXEO | ACP |
|---|---|---|
| Price | $9.93 | $5.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $18.90 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 337.9K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 17.79% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.45 | $5.55 |
| 52 Week High | $10.99 | $7.17 |
Technical Indicators
Market Signals| Indicator | LXEO | ACP |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 44.93 |
| Support Level | $10.02 | $5.38 |
| Resistance Level | $10.99 | $5.48 |
| Average True Range (ATR) | 0.59 | 0.04 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 45.64 | 32.14 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.